Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Gils · SciRah

Researcher profile · Semantic Scholar

A. Gils

Share profile

A. Gils — researcher profile on SciRah

h-index: 57
Works: 364
Citations: 11K

Most-cited papers

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
G. D'Haens, S. Vermeire, G. Lambrecht, F. Baert +22 more
2018Gastroenterology280 citations Open access
Semantic Scholar
Immunogenicity of biologics in inflammatory bowel disease
S. Vermeire, A. Gils, P. Accossato, S. Lula +1 more
2018Therapeutic Advances in Gastroenterology202 citations Open access
Semantic Scholar
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
E. Dreesen, B. Verstockt, Su-Min Bian, M. de Bruyn +7 more
2018Clinical Gastroenterology and Hepatology153 citations
Semantic Scholar
Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region
F. S. van de Bovenkamp, N. Derksen, Pleuni Ooijevaar-de Heer, K. V. van Schie +14 more
2018Proceedings of the National Academy of Sciences of the United States of America123 citations Open access
Semantic Scholar
Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates.
B. Verstockt, E. Dreesen, M. Noman, A. Outtier +7 more
2019Journal of Crohn's & Colitis99 citations Open access
Semantic Scholar
Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study.
C. Liefferinckx, B. Verstockt, A. Gils, M. Noman +15 more
2019Journal of Crohn's & Colitis93 citations Open access
Semantic Scholar
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
E. Dreesen, F. Baert, D. Laharie, P. Bossuyt +11 more
2020Clinical Gastroenterology and Hepatology81 citations Open access
Semantic Scholar
Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing
B. Verstockt, G. Moors, Su-Min Bian, T. van Stappen +4 more
2018Alimentary Pharmacology and Therapeutics67 citations Open access
Semantic Scholar
Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis
K. Papamichael, F. Baert, S. Tops, G. Van Assche +4 more
2017Journal of Crohn's & Colitis64 citations Open access
Semantic Scholar
Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
B. Verstockt, S. Verstockt, B. Creyns, S. Tops +6 more
2019Alimentary Pharmacology and Therapeutics59 citations Open access
Semantic Scholar
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
K. van Hoeve, E. Dreesen, I. Hoffman, G. Van Assche +3 more
2018Journal of Crohn's & Colitis57 citations
Semantic Scholar
Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response
E. Dreesen, T. van Stappen, V. Ballet, M. Peeters +7 more
2018Alimentary Pharmacology and Therapeutics43 citations Open access
Semantic Scholar
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
Niels Vande Casteele, F. Baert, Su-Min Bian, E. Dreesen +5 more
2019Journal of Crohn's & Colitis39 citations
Semantic Scholar
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease
K. van Hoeve, E. Dreesen, I. Hoffman, G. Van Assche +3 more
2019Journal of Pediatric Gastroenterology and Nutrition - JPGN37 citations Open access
Semantic Scholar
Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease.
Su-Min Bian, Jiadi Lu, F. Delport, S. Vermeire +3 more
2018Drug Testing and Analysis37 citations
Semantic Scholar
Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time
Su-Min Bian, E. Dreesen, Ho-Tsun Tang, G. Compernolle +5 more
2017Inflammatory Bowel Diseases37 citations
Semantic Scholar
Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients
Nathalie Van den Berghe, B. Verstockt, S. Tops, M. Ferrante +2 more
2019Journal of Gastroenterology and Hepatology34 citations
Semantic Scholar
Eczematous eruption after guselkumab treatment for psoriasis
B. Reyn, A. Gils, Tom Hillary
2019JAAD Case Reports32 citations Open access
Semantic Scholar
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease
K. van Hoeve, E. Dreesen, I. Hoffman, G. Van Assche +3 more
2019Therapeutic Drug Monitoring32 citations Open access
Semantic Scholar
Optimising infliximab induction dosing for patients with ulcerative colitis
E. Dreesen, R. Faelens, G. Van Assche, M. Ferrante +3 more
2019British Journal of Clinical Pharmacology32 citations Open access
Semantic Scholar
Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance
C. Liefferinckx, C. Minsart, A. Cremer, L. Amininejad +7 more
2019European Journal of Gastroenterology and Hepathology30 citations Open access
Semantic Scholar
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
J. Hanžel, N. Sever, I. Ferkolj, B. S̆tabuc +8 more
2019United European Gastroenterology journal29 citations Open access
Semantic Scholar
Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients.
B. Verstockt, E. Mertens, E. Dreesen, A. Outtier +7 more
2020Journal of Crohn's & Colitis28 citations Open access
Semantic Scholar
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab.
D. Tarabar, Katia El Jurdi, C. Traboulsi, O. Yvellez +9 more
2022Inflammatory Bowel Diseases27 citations
Semantic Scholar
Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases.
Henry Ordutowski, Francesco Dal Dosso, Wout De Wispelaere, C. Van Tricht +5 more
2022Biosensors & bioelectronics23 citations Open access
Semantic Scholar
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
E. Dreesen, S. Berends, D. Laharie, G. D'Haens +3 more
2020British Journal of Clinical Pharmacology23 citations Open access
Semantic Scholar
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
M. Bronswijk, A. Moens, M. Lenfant, S. Tops +5 more
2019Inflammatory Bowel Diseases22 citations Open access
Semantic Scholar
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
E. Dreesen, W. Kantasiripitak, I. Detrez, S. Stefanovic +5 more
2019Inflammatory Bowel Diseases20 citations Open access
Semantic Scholar
DOP047 Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX
E. Dreesen, G. D'Haens, F. Baert, B. Pariente +6 more
201820 citations Open access
Semantic Scholar
Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response
A. Outtier, L. Wauters, J. Rahier, P. Bossuyt +11 more
2021GastroHep19 citations Open access
Semantic Scholar
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance
C. Liefferinckx, C. Minsart, J. Toubeau, A. Cremer +6 more
2017Inflammatory Bowel Diseases17 citations Open access
Semantic Scholar
Infliximab Concentrations During Induction Are Predictive for Endoscopic Remission in Pediatric Patients With Inflammatory Bowel Disease Under Combination Therapy.
K. van Hoeve, Nasim Sadat Seyed Tabib, E. Dreesen, S. Tops +4 more
2021Jornal de Pediatria16 citations Open access
Semantic Scholar
P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients
J. Marini, A. Gils, G. Shankar, M. Peeters +6 more
201816 citations
Semantic Scholar
Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients
I. Detrez, Debby Thomas, K. van Steen, V. Ballet +6 more
2019Journal of Clinical Gastroenterology15 citations
Semantic Scholar
Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Nathalie Van den Berghe, A. Gils, Debby Thomas
2019Clinical pharmacology and therapy15 citations Open access
Semantic Scholar
Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step towards personalized therapy.
R. Soenen, E. Meulewaeter, L. Grine, Nathalie Van den Berghe +6 more
2019Journal of Investigative Dermatology15 citations Open access
Semantic Scholar
Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information
I. Detrez, G. Schops, J. Lefrère, S. Tops +5 more
2018AAPS Journal15 citations
Semantic Scholar
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases
W. Kantasiripitak, B. Verstockt, Dahham Alsoud, T. Lobatón +5 more
2021British Journal of Clinical Pharmacology13 citations Open access
Semantic Scholar
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
I. Detrez, A. Gils
2017Journal of Crohn's & Colitis13 citations Open access
Semantic Scholar
Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations.
Su-Min Bian, Nathalie Van den Berghe, L. Vandersmissen, S. Tops +4 more
2020Journal of Pharmaceutical and Biomedical Analysis12 citations Open access
Semantic Scholar
Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations.
Nathalie Van den Berghe, B. Verstockt, A. Gils, J. Sabino +4 more
2020Journal of Crohn's & Colitis12 citations Open access
Semantic Scholar
Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis: a retrospective observational study.
A. Berger, G. Duru, A. de Vries, J. Marini +7 more
2019Therapeutic Drug Monitoring11 citations
Semantic Scholar
Anti-infliximab antibodies: How to compare old and new data?
Maya Imbrechts, T. van Stappen, G. Compernolle, S. Tops +1 more
2020Journal of Pharmaceutical and Biomedical Analysis10 citations
Semantic Scholar
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
S. Stefanovic, I. Detrez, G. Compernolle, E. Brouwers +9 more
2020European Journal of Gastroenterology and Hepathology9 citations
Semantic Scholar
Pharmacodynamic monitoring of biological therapies in chronic inflammatory diseases.
E. Dreesen, A. Gils
2019Therapeutic Drug Monitoring9 citations
Semantic Scholar
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
M. Bronswijk, A. Moens, M. Lenfant, S. Tops +5 more
2019Inflammatory Bowel Diseases9 citations Open access
Semantic Scholar
A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor
T. Stanne, M. Olsson, E. Lorentzen, A. Pedersen +7 more
2018Thrombosis and Haemostasis9 citations Open access
Semantic Scholar
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases
C. Liefferinckx, B. Verstockt, A. Gils, S. Tops +3 more
2019United European Gastroenterology journal8 citations Open access
Semantic Scholar
Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study.
I. Gesquiere, N. Steenackers, M. Lannoo, V. Foulon +6 more
2019Journal of Trace Elements in Medicine and Biology8 citations Open access
Semantic Scholar
The association between etanercept serum concentration and psoriasis severity is highly age-dependent.
I. Detrez, K. van Steen, S. Segaert, A. Gils
2017Clinical science6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Vermeire×33
Invite
S. Vermeire — researcher profile on SciRah
M. Ferrante×25
Invite
M. Ferrante — researcher profile on SciRah
G. Van Assche×17
Invite
G. Van Assche — researcher profile on SciRah
S. Tops×15
Invite
S. Tops — researcher profile on SciRah

×12

Invite

E. Dreesen — researcher profile on SciRah

B. Verstockt×10

Invite

B. Verstockt — researcher profile on SciRah

G. Compernolle×10

Invite

G. Compernolle — researcher profile on SciRah

Invite

F. Baert — researcher profile on SciRah

Invite

I. Detrez — researcher profile on SciRah

D. Franchimont×6

Invite

D. Franchimont — researcher profile on SciRah

Invite

Su-Min Bian — researcher profile on SciRah

Nathalie Van den Berghe×6

Invite

Nathalie Van den Berghe — researcher profile on SciRah